abiraterone has been researched along with Invasiveness, Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisbjerg, R; Fode, M; Kistorp, CM; Kvorning Ternov, K; Lindberg, H; Palapattu, G; Sønksen, J; Østergren, PB | 1 |
| Agrawal, M; Almeida, F; Brown, A; Dicker, AP; Fernandez, DC; Garcia, JA; Gratt, J; Iagaru, A; Lutzky, J; Morris, MJ; Petrenciuc, O; Sartor, O; Shore, ND; Smith, MR; Sweeney, C; Vogelzang, NJ; Wong, YN | 1 |
| Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC | 1 |
| Castellano, D; Daugaard, G; De Porre, P; Galli, L; Garrido, JM; Géczi, L; George, DJ; Goon, B; Hotte, SJ; Lee, E; Londhe, A; Mainwaring, PN; McGowan, T; Molina, A; Naini, V; Saad, F; Souza, C; Sternberg, CN; Tay, MH; Todd, MB | 1 |
| Cookson, MS; Ritch, CR | 1 |
| Djavan, B; Farr, A; Herout, R; Margreiter, M; Tosev, G | 1 |
1 review(s) available for abiraterone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Advances in the management of castration resistant prostate cancer.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Management; Docetaxel; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
3 trial(s) available for abiraterone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Glucose; Clinical Trials, Phase III as Topic; Denmark; Fatigue; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms; Nitriles; Phenylthiohydantoin; Prognosis; Radium; Survival Rate | 2018 |
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisolone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2014 |
2 other study(ies) available for abiraterone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2014 |
New findings in bladder and prostate cancer: highlights from the 26th annual congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria.
Topics: Androstenes; Androstenols; Biomarkers; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Pelvis; Prostatectomy; Prostatic Neoplasms; Radioimmunotherapy; Urinary Bladder Neoplasms | 2011 |